CytomX Therapeutics (CTMX) Income from Continuing Operations (2014 - 2026)

CytomX Therapeutics has reported Income from Continuing Operations for 13 years, with the latest figure at 18248000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations fell 177.57% year-over-year to 18248000.0; the trailing twelve-month figure through Mar 2026 stood at 59141000.0 (down 242.16% YoY), and the FY2025 full-year result was 17368000.0, down 154.5% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 18248000.0, up from 26510000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 23525000.0 in Q1 2025, with the low at 31981000.0 in Q1 2022.
• Historically, Income from Continuing Operations has averaged 6096000.0 across 5 years, with a median of 3311000.0 in 2023.
• The largest YoY upside for Income from Continuing Operations was 2155.2% in 2024 against a maximum downside of 501.1% in 2024.
• CytomX Therapeutics' Income from Continuing Operations stood at 8775000.0 in 2022, then soared by 109.54% to 837000.0 in 2023, then jumped by 2155.2% to 18876000.0 in 2024, then tumbled by 240.44% to 26510000.0 in 2025, then jumped by 31.17% to 18248000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 18248000.0 (Q1 2026), 26510000.0 (Q4 2025), and 14229000.0 (Q3 2025), per Business Quant data.